Working and safety profiles of JAK/STAT signaling inhibitors. Are these small molecules also smart?

E Favoino, M Prete, G Catacchio, P Ruscitti… - Autoimmunity …, 2021 - Elsevier
The Janus kinase (JAK)/signal transducers and activators of transcription (STAT) pathway is
an important intracellular route through which many different extracellular soluble …

Genetic background of polycythemia vera

M Regimbeau, R Mary, F Hermetet, F Girodon - Genes, 2022 - mdpi.com
Polycythemia vera belongs to myeloproliferative neoplasms, essentially by affecting the
erythroblastic lineage. JAK2 alterations have emerged as major driver mutations triggering …

Antagonistic activities of the immunomodulator and PP2A-activating drug FTY720 (Fingolimod, Gilenya) in Jak2-driven hematologic malignancies

JJ Oaks, R Santhanam, CJ Walker… - Blood, The Journal …, 2013 - ashpublications.org
Abstract FTY720 (Fingolimod, Gilenya) is a sphingosine analog used as an
immunosuppressant in multiple sclerosis patients. FTY720 is also a potent protein …

Critical requirement for Stat5 in a mouse model of polycythemia vera

D Yan, RE Hutchison, G Mohi - Blood, The Journal of the …, 2012 - ashpublications.org
The JAK2V617F mutation has been identified in most cases of Ph-negative
myeloproliferative neoplasms (MPNs) including polycythemia vera (PV), essential …

Erythropoietin pathway: a potential target for the treatment of depression

C Ma, F Cheng, X Wang, C Zhai, W Yue, Y Lian… - International journal of …, 2016 - mdpi.com
During the past decade, accumulating evidence from both clinical and experimental studies
has indicated that erythropoietin may have antidepressant effects. In addition to the kidney …

A general approach to synthesize asymmetric hybrid nanoparticles by interfacial reactions

J He, MT Perez, P Zhang, Y Liu, T Babu… - Journal of the …, 2012 - ACS Publications
Asymmetric multicomponent nanoparticles (AMNPs) offer new opportunities for new-
generation materials with improved or new synergetic properties not found in their individual …

Genetics of myeloproliferative neoplasms

AD Viny, RL Levine - The Cancer Journal, 2014 - journals.lww.com
In the last decade, genomic studies have identified multiple recurrent somatic mutations in
myeloproliferative neoplasms (MPNs). Beginning with the discovery of the JAK2 V617F …

Efficacy of vorinostat in a murine model of polycythemia vera

H Akada, S Akada, A Gajra, A Bair… - Blood, The Journal …, 2012 - ashpublications.org
The discovery of the JAK2V617F mutation in most patients with Ph-negative
myeloproliferative neoplasms has led to the development of JAK2 kinase inhibitors …

A structure-function perspective of Jak2 mutations and implications for alternate drug design strategies: the road not taken

K Gnanasambandan, PP Sayeski - Current medicinal chemistry, 2011 - ingentaconnect.com
Jak2 is a non-receptor tyrosine kinase that is involved in the control of cellular growth and
proliferation. Due to its significant role in hematopoiesis, Jak2 is a frequent target for …

Essential thrombocytosis attributed to JAK2-T875N germline mutation

M Yoshimitsu, M Hachiman, Y Uchida, N Arima… - International Journal of …, 2019 - Springer
The aim of this study was to elucidate the role of a non-canonical JAK2 mutation JAK2-
T875N, which was identified by exome sequencing in a patient with essential …